<!DOCTYPE html>
<html lang="en">
<head>
    <title>Toujeo</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta http-equiv="X-UA-Compatible" content="IE=edge"/>
    <link href="https://fonts.googleapis.com/css?family=Muli" rel="stylesheet">
    <link rel="stylesheet" href="style.css">
</head>
<body>
<table class="wrapperMain" align="center" cellpadding="0" cellspacing="0" border="0">
    <tr>
        <td class="clickHere">
            <a href="#">Click here</a> to get free sample delivery to your door.
        </td>
    </tr>
    <tr>
        <td class="headerTop">
            <table class="headerTop__inner" cellpadding="0" cellspacing="0">
                <tr>
                    <td class="column" align="left" valign="top">
                        <a href="#">View in browser</a>
                    </td>
                    <td class="column" align="left" valign="top">
                        <a href="#">ToujeoPro.com</a>
                    </td>
                    <td class="column" align="left" valign="top">
                        <a href="#">Unsubscribe</a>
                    </td>
                    <td class="column" align="right" valign="top">
                        <img src="img/sanofi.jpg" alt="">
                    </td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td class="headerBottom">
            <table class="headerBottom__inner" cellpadding="0" cellspacing="0">
                <tr>
                    <td class="column" align="left" valign="top">
                        <img src="img/toujeo.jpg" alt="">
                    </td>
                    <td class="column" align="left" valign="top">
                        <div class="footerBottom__textWrap">
                            <div>
                                <a href="#">Read Indication and<br>Full Important Safety Information</a>
                            </div>
                            <div>
                                <a href="#">Full Prescribing Information</a>
                            </div>
                        </div>
                    </td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td class="mainInfo">
            <table class="mainInfo__inner" cellpadding="0" cellspacing="0">
                <tr class="mainInfo__top">
                    <td class="mainInfo__patient">
                        Significant A1C reduction and demonstrated safety in a board range of adoult patient
                    </td>
                    <td class="mainInfo__space"></td>
                </tr>
                <tr class="mainInfo__middle">
                    <td class="mainInfo__wrapText">
                        <table cellpadding="0" cellspacing="0">
                            <tr>
                                <td class="mainInfo__text">
                                    See the clinical results patients like Ray wereable to achieve on
                                    Toujeo<sup>&reg;</sup></td>
                                <td class="mainInfo__arrow">
                                    <img src="img/arrow.jpg" alt="arrow"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr class="mainInfo__bottom">
                    <td colspan="2" class="mainInfo__bottomInner">
                        <table cellpadding="0" cellspacing="0">
                            <tr>
                                <td>
                                    Meet Ray...
                                </td>
                            </tr>
                        </table>
                        <table cellpadding="0" cellspacing="0">
                            <tr>
                                <td>
                                    <div class="square"></div>
                                </td>
                                <td>48-year-old insulin-naive patient with
                                    T2DM
                                </td>
                            </tr>
                            <tr>
                                <td>
                                    <div class="square"></div>
                                </td>
                                <td>Plays guitar in a jazz band</td>
                            </tr>
                            <tr>
                                <td>
                                    <div class="square"></div>
                                </td>
                                <td>Constantly on the go</td>
                            </tr>
                        </table>
                        <table>
                            <tr>
                                <td>
                                    He needs to improve his glycemic control
                                </td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td class="textInfo">
            In the EDITION 3 study, insulin-naive patients treated with Toujeo<sup>&reg;</sup> achieved signiticant A1C
            reduction and had a low incidence of severe hypoglycemia
        </td>
    </tr>
    <tr>
        <td class="percentage">
            <table class="percentage__inner" cellpadding="0" cellspacing="0">
                <tr>
                    <td colspan="2">Powerful A1C reductions over 26 weeks<sup>1</sup></td>
                </tr>
                <tr>
                    <td class="column">
                        <table align="center" class="mob-full-width" cellpadding="0" cellspacing="0">
                            <tr>
                                <td>
                                    -1.42%
                                </td>
                                <td class="fs14">Toujeo<sup>&reg;</sup><br>n=432</td>
                            </tr>
                        </table>
                    </td>
                    <td class="column">
                        <table align="center" class="mob-full-width" cellpadding="0" cellspacing="0">
                            <tr>
                                <td>-1.46%</td>
                                <td class="fs12">Lantus<sup>&reg;</sup><br>n=430</td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </table>
            <table class="percentage__inner" cellpadding="0" cellspacing="0">
                <tr>
                    <td colspan="2">Demonstrated safety<sup>1</sup></td>
                </tr>
                <tr>
                    <td class="column">
                        <table align="center" class="mob-full-width" cellpadding="0" cellspacing="0">
                            <tr>
                                <td>0.9%</td>
                                <td class="fs16">Low incidence of severe hypoglycemia<sup>a</sup></td>
                            </tr>
                        </table>
                    </td>
                    <td class="column">
                        <table align="center" class="mob-full-width" cellpadding="0" cellspacing="0">
                            <tr>
                                <td>8%</td>
                                <td class="fs16">Documented symptomatic hypoglycemia<sup>b</sup></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td class="note">*Severe hypoglycemia: an event requiring assistance of
            another person to actively administer a resuscitative action.
        </td>
    </tr>
    <tr>
        <td class="note">Documented symptomatic hypoglycemia: an event with typical
            symptoms of hypoglycemia accompanied by a self-rnonitored or plasma glucose value s54 mg/dL.
        </td>
    </tr>
    <tr>
        <td class="list">
            <table class="list__inner">
                <tr>
                    <td>
                        <div class="square"></div>
                    </td>
                    <td>Most common adverse events (with incidence >5%)
                        with Toujeo® in patients with T2DM were nasopharyngitis (7.1%) and upper respiratory tract
                        infection (5.7%)<sup>1</sup></td>
                </tr>
            </table>
            <table class="list__inner">
                <tr>
                    <td>
                        <div class="square"></div>
                    </td>
                    <td>Incidence of severe hypoglycemia when part of a
                        multiple-dose injection regimen: 6.6% in T1DM; 5% in T2DM; when part of a basal insulin-only
                        regimen: 1.0% and 0.9% in two T2DM studies<sup>1</sup></td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td class="infoBlock">
            <span class="bold">EDITION 3 Study Design:</span> Toujeo<sup>&reg;</sup> was compared with
            Lantus* in a 26-week, noninferiority, open-label study of 862 insulin-naive adults with T2DM who were not at
            goal (A1C range: 7%-11%). Patients were randomized to either Toujeo<sup>&reg;</sup> or
            Lantus<sup>&reg;</sup> once daily as part of a regimen with noninsulin antidiabetic drugs. All patients were
            titrated to an FPG goal of 80-100 mg/dL, mainly during the first 12 weeks of treatment.<sup>1,2</sup>
        </td>
    </tr>
    <tr>
        <td class="readFull">
            <a href="#">Read the full EDITION 3 study
                abstract at PubMed.gov</a>
        </td>
    </tr>
    <tr>
        <td class="seeEdition">
            <table class="seeEdition__inner" cellpadding="0" cellspacing="0">
                <tr>
                    <td class="column">
                        <table class="seeEdition__button" cellpadding="0" cellspacing="0">
                            <tr>
                                <td>See EDITION 2 data</td>
                                <td><img src="img/arrow-blue.jpg" alt="arrow"></td>
                            </tr>
                        </table>
                    </td>
                    <td class="column">
                        <table class="seeEdition__button" cellpadding="0" cellspacing="0">
                            <tr>
                                <td>See EDITION 1 data</td>
                                <td><img src="img/arrow-blue.jpg" alt="arrow"></td>
                            </tr>
                        </table>
                    </td>
                    <td class="column">
                        <table class="seeEdition__button" cellpadding="0" cellspacing="0">
                            <tr>
                                <td>See EDITION 4 data</td>
                                <td><img src="img/arrow-blue.jpg" alt="arrow"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td class="register">
            <table class="register__inner" cellpadding="0" cellspacing="0">
                <tr>
                    <td colspan="2">Get free samples of Toujeo quickly and easily.</td>
                </tr>
                <tr>
                    <td class="column"><img src="img/pills.jpg" alt="pills"></td>
                    <td class="column">
                        <table cellpadding="0" cellspacing="0">
                            <tr>
                                <td>Register for samples</td>
                                <td><img src="img/arrow.jpg" alt="arrow"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td class="registerNote">
            T2DM, type 2 diabets mellitus. T1DM, type 1 diabetes mellitus, FPG, fasting plasma glucose.
        </td>
    </tr>
    <tr>
        <td>
            <table cellpadding="0" cellspacing="0" style=" padding: 0 30px; line-height: 1.2;">
                <tr>
                    <td>
                        Toujeo<sup>&reg;</sup> is a long-acting human insulin analog indicated to improve glycemic
                        control in adults with diabetes mellitus.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Limitations of Use: Toujeo<sup>&reg;</sup> is not recommended for treating diabetic
                        ketoacidosis.
                    </td>
                </tr>
                <tr>
                    <td class="title">
                        Important Safety Information for Toujeo<sup>&reg;</sup> (insulin glargine injection) 300
                        Units/mL
                    </td>
                </tr>
                <tr>
                    <td class="subtitle2">
                        Contraindications
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Toujeo<sup>&reg;</sup> is contraindicated during episodes of hypoglycemia and in patients
                        hypersensitive to insulin glargine or any of its excipients.
                    </td>
                </tr>
                <tr>
                    <td class="subtitle2">
                        Warnings and Precautions
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 6px;">
                        Toujeo” contains the same active ingredient, insulin glargine, as LantusThe concentration of
                        insulin glargine in Toujeo<sup>&reg;</sup> is 300 units per mL.
                    </td>
                </tr>
                <tr>
                    <td class="subtitle">
                        Insulin pens and needles must never be shared between patients. Do NOT reuse needles.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously
                        and only under medical supervision. Changes in insulin strength, manufacturer, type, or method
                        of administration may result in the need for a change in insulin dose or an adjustment in
                        concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia
                        or hypoglycemia.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Unit for unit, patients started on, or changed to, Toujeo<sup>&reg;</sup> required a higher dose
                        than patients controlled with Lantus<sup>&reg;</sup>. When changing from another basal insulin
                        to Toujeo<sup>®</sup>, patients experienced higher average fasting plasma glucose levels in the
                        first few weeks of therapy until titrated to their individualized fasting plasma glucose
                        targets. Higher doses were required in titrate-to-target studies to achieve glucose control
                        similar to Lantus’’.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Hypoglycemia is the most common adverse reaction of insulin therapy, including
                        Toujeo<sup>&reg;</sup>, and may be life-threatening.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Medication errors such as accidental mix-ups between basal insulin products and other insulins,
                        particularly rapid-acting insulins, have been reported. Patients should be instructed to always
                        verify the insulin label before each injection.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Do not dilute or mix Toujeo<sup>&reg;</sup> with any other insulin or solution. If mixed or
                        diluted, the solution may become cloudy, and the onset of action/time to peak effect may be
                        altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or
                        intravenously because severe hypoglycemia can occur.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue
                        Toujeo<sup>®</sup>, monitor and treat if indicated.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        A reduction in the Toujeo<sup>&reg;</sup> dose may be required in patients with renal or hepatic
                        impairment.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        As with all insulins, Toujeo use can lead to life-threatening hypokalemia. Untreated hypokalemia
                        may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium
                        levels in patients at risk of hypokalemia and treat if indicated.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use
                        of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and
                        symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD
                        must be considered.
                    </td>
                </tr>
                <tr>
                    <td class="subtitle2">
                        Drug Interactions
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close
                        monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking
                        anti-adrenergic drugs (eg, beta-blockers, clonidine, guanethidine, and reserpine).
                    </td>
                </tr>
                <tr>
                    <td class="subtitle2">
                        Adverse Reactions
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Adverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions,
                        injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.
                    </td>
                </tr>
                <tr>
                    <td class="title">
                        Important Safety Information for Toujeo<sup>&reg;</sup> (insulin glargine injection) 300
                        Units/mL SoloStar<sup>&reg;</sup>
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Toujeo<sup>&reg;</sup> SoloStar<sup>&reg;</sup> is a disposable prefilled insulin pen.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        To help ensure an accurate dose each time, patients should follow all steps in the Instruction
                        Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which
                        may affect their blood glucose levels.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        Do not withdraw Toujeo<sup>&reg;</sup> from the SoloStar2 disposable prefilled pen with a
                        syringe.
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        <a class='link' href="#">Click here for full Prescribing Information.</a>
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        <a class='link' href="#">Click here for information on sharps medical waste disposal.</a>
                    </td>
                </tr>
                <tr>
                    <td style="padding-bottom: 10px;">
                        <a class='link' href="#">Click here to learn more about Sanofi’s commitment to fighting
                            counterfeit drugs.</a>
                    </td>
                </tr>
                <tr>
                    <td style="font-size: 10px; padding-bottom: 50px; color: black">
                        <strong>References: 1.</strong> Toujeo Prescribing Information. <strong>2.</strong> Bolfc GB.
                        Riddle MC. Bergenstal RM, ct al. <i>Diabetes Obes Metab</i> 2015:17(4):386-394.
                    </td>
                </tr>
            </table>
        </td>
    </tr>
    <tr>
        <td style="padding: 0 15px 87px">
            <table width="100%" cellspacing="15" cellpadding="0" border="0"
                   style="background-color: #ffffff; font-size: 14px;">
                <tr>
                    <td>Pelease do DO NOT REPLY TO THIS EMAIL. Sanofi US will not receive this message if you reply.
                        Should you have any questions regarding this email or Sanofy US, please contact us at the below
                        address, toll free number or URL.
                    </td>
                </tr>
                <tr>
                    <td>
                        Sanofy US<br>
                        55 Corporate Drive<br>
                        Bridgewater, NJ 08807<br>
                        Tel: 1-800-981-2491<br>
                        <a href="https://contactus.sanofi.us" class="link-blue">https://contactus.sanofi.us</a>
                    </td>
                </tr>
                <tr>
                    <td>
                        <a href="#" class="link-blue"><img src="img\logo_sanofi.jpg" alt="logo sanofi"></a>
                    </td>
                </tr>
                <tr>
                    <td>
                        This promotional material has been provided to you by Sanofi. You may unsubscribe by
                        <a href="#" class="link-blue">clicking here</a> or by calling 1-800-633-1610
                    </td>
                </tr>
                <tr>
                    <td>
                        © 2018 sanofi-aventis U.S. LLC. All rights reserved.<br>
                        SAUS.TJO.18.01.0233 <span>01/18</span>
                    </td>
                </tr>
            </table>
        </td>
    </tr>
</table>
</body>
</html>